BridgeBio Pharma, Inc. announced that its investigational drug Encaleret for ADH1 (Autosomal Dominant Hypocalcemia Type 1) achieved positive results in the Phase 3 CALIBRATE clinical trial.

Based on the successful data from this pivotal study, the company has clearly planned to submit a New Drug Application (NDA) to regulatory authorities in the first half of 2026. The breakthrough progress in the trial results has brought new hope for treatment to the ADH1 rare disease patient group. The company stated that it will make every effort to advance the subsequent application preparation work to ensure the NDA submission is completed on schedule.